Clinical Trials
12 trialsNCT04781192 2026-01-23
The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers
University of Kansas Medical Center
Phase 1/2 Active not recruiting
NCT04172402 2025-07-22
NGS as the First-line Treatment in Advanced Biliary Tract Cancer
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT06708858 2024-11-27
Phase â…¡ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer
Chinese PLA General Hospital
Phase 2 Recruiting
NCT04727996 2024-04-19
BTC-BGB
Seoul National University Hospital
Phase 2 Unknown
NCT05820906 2023-12-06
Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Unknown
NCT05812430 2023-09-13
Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer
The First Affiliated Hospital of Zhengzhou University
Phase 2 Unknown
NCT05823987 2023-06-27
OPTIONS-05
Fudan University
Phase 2 Unknown
NCT04217954 2023-06-23
HAIC With Oxaliplatin, 5-FU and Bevacizumab Plus Intravenous Toripalimab for Advanced BTC
Peking University
Phase 2 Completed
NCT05781074 2023-03-24
CASTLE-08
Fudan University
Phase 2 Unknown
NCT05410197 2022-10-12
Envofolimab and Lenvatinib Combined With Gemcitabine Plus Cisplatin for Advanced BTC as First-Line Treatment(ENLIGHTEN)
Sun Yat-sen University
Phase 2 Unknown
NCT04027764 2019-07-22
Toripalimab Combined With S1 and Albumin Paclitaxel in Patients With Advanced Biliary Tract Cancer
Chinese PLA General Hospital
Phase 2 Unknown
NCT03358849 2019-01-16
Phase 1 Clinical Trial to Evaluate the Safety of Allogeneic NK Cell ("SMT-NK") Cell Therapy in Advanced Biliary Tract Cancer
Yonsei University
Phase 1 Completed